Search

Your search keyword '"Adda M"' showing total 296 results

Search Constraints

Start Over You searched for: Author "Adda M" Remove constraint Author: "Adda M"
296 results on '"Adda M"'

Search Results

1. Direct determination of chronic myeloid leukemia prevalence in Lombardy—Italy: Global implications.

5. On-line determination of stellar atmospheric parameters Teff, log g, [Fe/H] from ELODIE echelle spectra. I - The method

7. Interconnection of transputer links using a multiple bus configuration

9. Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study

10. ESICM LIVES 2016: part three: Milan, Italy. 1–5 October 2016

11. Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19

12. Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study

14. Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia

15. Antifungal therapy for patients with proven or suspected Candida peritonitis: Amarcand2, a prospective cohort study in French intensive care units

16. Treatment patterns in patients with chronic-phase chronic myeloid leukaemia in routine clinical practice: The simplicity Italian population

17. PH plus STEM CELLS (SCS) IN CHRONIC MYELOID LEUKEMIA (CML): TO ERADICATE OR NOT TO ERADICATE, THIS IS THE QUESTION

18. IDENTIFICAZIONE DI MIRNA E GENI TARGET NELL’ANALISI TRASCRITTOMICA DELLE CELLULE CD34+/LIN- DI PAZIENTI CON LEUCEMIA MIELOIDE CRONICA IN FASE CRONICA DOPO 12 MESI DI TERAPIA CON NILOTINIB

19. Progressive Down Regulation of JAK-STAT, Cell Cycle, and ABC Transporter Genes in CD34+/Lin- Cells of Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients at Diagnosis Vs. 12 Months of Nilotinib Treatment Vs. Healthy Subjects

20. Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study)

23. IDENTIFICAZIONE DI MIRNA E GENI TARGET NELL’ANALISI TRASCRITTOMICA DELLE CELLULE CD34+/LIN- DI PAZIENTI CON LEUCEMIA MIELOIDE CRONICA IN FASE CRONICA DOPO 12 MESI DI TERAPIA CON NILOTINIB

24. Wide-transcriptome analysis and cellularity of bone marrow CD34+/lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment

25. Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers

26. Nilotinib induced bone marrow CD34+/lin–Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemia

27. Combining Imatinib-Following-Nilotinib Treatment in First Line Therapy for Chronic Phase Chronic Myeloid Leukemia. Update from the PhilosoPhi34 Study at 24 Months of Follow-up

28. Identification of genes differently expressed between bone marrow CD34+/LIN-cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs 12 months of first-line nilotinib treatment

29. Nilotinib Deregulates Cell Cycle Checkpoints, ABC Transporters Genes and JAK-STAT Signaling Pathway of CD34+/Lin- Cells in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients after 12 Months of Treatment

30. Jak-2 and Nfkbia Gene Expression Play a Strategic Role in Chronic Myeloid Leukemia (CML) Molecular Response during Early Nilotinib Treatment: The PhilosoPhi34 Data

31. Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study

34. Identification of genes differently expressed between bone marrow CD34+/LIN-cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs 12 months of first-line nilotinib treatment

35. Preliminary Experience of Imatinib after Nilotinib in the First Line Treatment of Chronic Myeloid Leukemia

36. IDENTIFICATION OF MIRNA AND TARGET GENES IN THE TRANSCRIPTOME ANALYSIS OF CD34+/LIN- CELLS OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN THE CHRONIC PHASE AFTER 12 MONTHS OF NILOTINIB THERAPY

38. COROT: High photometry stability with CCDs

39. Treatment patterns in patients with chronic-phase chronic myeloid leukaemia in routine clinical practice: The simplicity Italian population

40. Gene Expression Profiling and Cellularity of Bone Marrow CD34+/Lin- Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia at Diagnosis Vs. 12 Months of First-Line Nilotinib Treatment

41. DIFFERENT SETS OF GENES WERE ASSOCIATED TO THE MOLECULAR RESPONSE AFTER 3 AND 6 MONTHS OF FIRST-LINE NILOTINIB TREATMENT BY MICROARRAY OF CD34+/LIN- CELLS OF CHRONIC PHASE CML PATIENTS AT DIAGNOSIS

42. Jak-2 and Nfkbia Gene Expression Play a Strategic Role in Chronic Myeloid Leukemia (CML) Molecular Response during Early Nilotinib Treatment: The PhilosoPhi34 Data

43. PS1190 R-INTERFERON TREATMENT BEFORE TKI START IMPROVES TREATMENT FREE REMISSION RATE (TFR) PARTICULARLY IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH THE LESS FAVORABLE E13A2 BCR-ABL1 TRANSCRIPT TYPE

44. PF688 JAK2 ALLELIC RATIO IMPACTS ON VASCULAR EVENT IN MYELOFIBROSIS BY INCREASING THE RISK OF THROMBOSIS. A SINGLE CENTER EXPERIENCE ON 150 PATIENTS

45. S882 OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY

46. PS1462 SECOND PRIMARY MALIGNANCIES IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: REAL WORLD EVIDENCE FROM 215 CONSECUTIVELY TREATED PATIENTS IN LOMBARDY

47. S1646 THE COMBINATION OF LOW ADAMTS-13 ACTIVITY AND HIGH ANTI-ADAMTS13 ANTIBODIES AT REMISSION HIGHLY PREDICTS DISEASE RELAPSE IN PATIENTS WITH ACQUIRED TTP: A MULTI-INSTITUTIONAL STUDY

48. DIFFERENT SETS OF GENES WERE ASSOCIATED TO THE MOLECULAR RESPONSE AFTER 3 AND 6 MONTHS OF FIRST-LINE NILOTINIB TREATMENT BY MICROARRAY OF CD34+/LIN- CELLS OF CHRONIC PHASE CML PATIENTS AT DIAGNOSIS

49. REL-PROTOCOL PHILOSOPHI34 CONFIRMS THAT NILOTINIB RAPIDLY INDUCES CD34+/LIN-PH+ CELLS DISAPPEARANCE IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA (CML) IN CHRONIC PHASE (CP)

50. ESTABLISHING A NATIONAL NETWORK OF LABORATORIES USING NEXT GENERATION AMPLICON DEEP SEQUENCING FOR BCR-ABL1 KINASE DOMAIN MUTATION SCREENING: THE 'NEXT-IN-CML' STUDY

Catalog

Books, media, physical & digital resources